INTERASPIRE研究:冠心病患者血压低于目标值的患病率与特征
INTERASPIRE研究在14国纳入4548例近期因冠心病住院的患者,测量坐位血压并按2023 ESH与2024 ESC指南分类。结果显示10.3%患者血压在目标范围120-129/70-79 mm Hg,53.9%高于目标,35.7%低于目标(<120/70 mm Hg)。低于目标者更多合并心衰、eGFR<60及严重衰弱,但降压药数量与累积剂量未更高。
要点
- 超过三分之一冠心病患者血压低于120/70 mm Hg,低于现行欧洲指南目标。
- 低于目标血压者更多合并心衰、肾功能不全和严重衰弱。
- 低于目标组降压药数量与累积剂量并未高于达标组。
核心结论
- 超过三分之一的INTERASPIRE冠心病患者血压低于120/70 mm Hg,低于当前欧洲高血压指南目标。
研究设计与样本
- INTERASPIRE研究于2020-2023年在14国纳入近期因冠心病住院的成人,进行标准化访谈和检查,测量坐位血压两次。
- 共纳入4548例参与者(女性21.1%),平均年龄60.0±10.3岁。
主要发现
- 在冠心病住院后中位1.05(IQR 0.76-1.45)年,10.3%患者血压在120-129/70-79 mm Hg目标范围,53.9%高于目标,35.7%低于目标(<120/70 mm Hg)。
- 与达标者相比,低于目标者更可能有心衰(13.6% vs 10.0%,p=0.041)和eGFR<60 mL/min/1.73 m²(18.9% vs 10.7%,p<0.001)。
- 低于目标者严重衰弱的可能性在统计学上更高(p=0.030)。
- 三个血压目标组间降压药中位数无显著差异,低于目标组降压药累积剂量也未比达标组更强。
关键数值与推荐
- 血压高于目标定义为≥130/80 mm Hg,达标为120-129/70-79 mm Hg,低于目标为<120/70 mm Hg,依据2023 ESH和2024 ESC指南。
- 2023 ESH指南对主动避免血压低于目标给出Class 3推荐,而2024 ESC指南未作此推荐。
临床怎么用
- 对冠心病合并心衰、肾功能不全或衰弱的患者,应关注血压是否低于120/70 mm Hg。
- 低于目标血压者降压药数量与累积剂量并未更高,提示需个体化评估而非仅依据血压数值调整治疗。
局限性
- 血压仅测量两次,未报告24小时动态血压。
- 研究为观察性设计,无法确定低于目标血压与结局的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite treatment, many hypertensive patients with coronary heart disease (CHD) have blood pressure (BP) that remains above guideline targets. However, less is known about patients in whom on-treatment BP is below target and major European guidelines differ substantially in their recommendations for such patients. Specifically, 2023 European Society of Hypertension (ESH) guidelines provide a Class 3 recommendation to proactively avoid BP below target whereas 2024 European Society of Cardiology (ESC) guidelines do not. METHODS: Between 2020 and 2023, adults hospitalised in the previous 6-24 months with incident or recurrent CHD were sampled in 14 countries from all six WHO regions and invited for a standardised interview and examination as part of the International Action on Secondary and Primary Prevention by Intervention to Reduce Events (INTERASPIRE) study. We measured seated BP twice using an automated oscillometric device after 5 min of rest. We defined participants as having BP above target (BP ≥130/80 mm Hg), at target (BP 120-129/70-79 mm Hg) or below target (<120/70 mm Hg); according to both 2023 ESH and 2024 ESC guidelines. RESULTS: Among 4548 participants (21.1% female), the mean age (±SD) was 60.0 (±10.3) years. At a median (IQR) of 1.05 (0.76-1.45) years after index CHD hospitalisation, 10.3% of patients had BP readings within the target range of 120-129/70-79 mm Hg, with 53.9% above target and 35.7% below target. Patients with below-target BP were more likely to have heart failure (13.6% vs 10.0%, p=0.041) and estimated glomerular filtration rate <60 mL/min/1.73 m² (18.9% vs 10.7%, p<0.001), when compared with those at target. They were also statistically more likely to be severely frail (p=0.030). The median number of BP-lowering medications did not differ significantly between the 3 BP target groups. Cumulative dosing of BP-lowering medications in the below-target group was also not more intensive than that in the at-target group. CONCLUSIONS: More than one-third of INTERASPIRE patients with CHD presented with BP <120/70 mm Hg, which is below target per current European hypertension guidelines. Further research is needed in this population to resolve discordant guideline recommendations and determine whether de-escalation of BP-lowering therapies is beneficial or even harmful in this setting.
引用
- McCormick JP, De Bacquer D, Jennings C, et al. Prevalence and characteristics of patients with coronary heart disease and blood pressure below target: the INTERASPIRE study. Heart. 2026. PMID: 41887758. doi:10.1136/heartjnl-2025-327413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。